Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
Portage Biotech Inc (PRTG)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/10/2025: PRTG (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -71.87% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance 1.0 | Stock Returns Performance 1.0 |
Profits based on simulation | Last Close 01/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.72M USD | Price to earnings Ratio - | 1Y Target Price 140 |
Price to earnings Ratio - | 1Y Target Price 140 | ||
Volume (30-day avg) 1308991 | Beta 99.48 | 52 Weeks Range 2.10 - 25.15 | Updated Date 01/15/2025 |
52 Weeks Range 2.10 - 25.15 | Updated Date 01/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -68.17 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.42% | Return on Equity (TTM) -191.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2983658 | Price to Sales(TTM) - |
Enterprise Value 2983658 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.02 | Shares Outstanding 1121060 | Shares Floating 595206 |
Shares Outstanding 1121060 | Shares Floating 595206 | ||
Percent Insiders 29.81 | Percent Institutions 17.8 |
AI Summary
Portage Biotech Inc.: A Comprehensive Overview
Company Profile
History and Background:
Portage Biotech Inc. (PRTG), formerly known as Portage Pharmaceuticals, Inc., was founded in 2011 in Ann Arbor, Michigan. Initially, the company focused on developing novel pharmaceuticals for the treatment of gastrointestinal diseases. In 2016, Portage shifted its focus to developing RNA-based therapeutics for diseases with large unmet medical needs. This shift came after positive preclinical data for their lead candidate, PGT-301, in Friedreich's Ataxia.
Core Business Areas:
Currently, Portage Biotech is primarily focused on the discovery and development of novel RNA-based therapies. This includes:
- Small interfering RNA (siRNA): SiRNA molecules are designed to silence specific genes involved in disease pathogenesis. Portage is exploring siRNA therapies for Friedreich's Ataxia, Amyotrophic Lateral Sclerosis (ALS), and other neurological disorders.
- MicroRNA (miRNA): miRNA molecules regulate gene expression and can be used to restore or silence the expression of specific genes. Portage is exploring miRNA therapies for Duchenne Muscular Dystrophy (DMD) and other neuromuscular disorders.
Leadership and Corporate Structure:
- CEO: Dr. Ian Walters: Extensive experience in the pharmaceutical industry, having held leadership positions at several major companies.
- President & COO: Dr. Mark McCamish: Proven track record in developing and commercializing pharmaceutical products.
- CFO & Treasurer: Brian Markison: Strong financial expertise & experience in managing public companies.
Top Products and Market Share:
Portage's development pipeline currently consists of two lead candidates:
- PGT-301: A siRNA therapy for Friedreich's Ataxia. It is currently in a Phase 3 clinical trial.
- PRG-342: A miRNA therapy for DMD. It is currently in a Phase 1b/2a clinical trial.
Neither PGT-301 nor PRG-342 are commercially available yet; therefore, they have no current market share.
Competitive Landscape:
Portage competes with several other companies developing RNA-based therapies. Key competitors include Arrowhead Pharmaceuticals (ARWR), Dicerna Pharmaceuticals (DRNA), and Akcea Therapeutics (AKCA).
- Portage: Strong preclinical data and promising clinical progress for both PGT-301 and PRG-342.
- Arrowhead Pharmaceuticals: More advanced clinical pipeline with multiple ongoing Phase 3 trials.
- Dicerna Pharmaceuticals: Strong technology platform and several drug candidates in Phase 2 development.
- Akcea Therapeutics: First approved RNA-based therapy for a rare genetic disease (Tegsedi), established commercial presence.
Total Addressable Market
The global market for RNA-based therapies is estimated to reach $15 billion by 2025. The specific markets for Friedreich's Ataxia, ALS, DMD, and other diseases targeted by Portage are estimated to be in the hundreds of millions of dollars.
Financial Performance
Portage is currently in the development stage and has not yet generated any revenue from product sales. However, the company has reported increasing net losses in recent years due to ongoing clinical trials and research & development activities.
Dividends and Shareholder Returns
Portage is currently not paying any dividends and focuses on reinvesting its resources in R&D and clinical development.
Growth Trajectory
Portage has shown strong growth in its operations and clinical development programs in recent years. Key milestones include:
- Completion of Phase 2 clinical trial for PGT-301 in Friedreich's Ataxia.
- Initiation of Phase 3 clinical trial for PGT-301 in Friedreich's Ataxia.
- Completion of Phase 1b and initiation of Phase 2 clinical trial for PRG-342 in DMD.
Portage's future growth will depend on the success of its clinical trials and potential commercialization of its therapies.
Market Dynamics
The RNA-based therapeutics market is rapidly growing, driven by advancements in technology and increasing recognition of the potential of these therapies to treat serious diseases. However, competition is intensifying, and regulatory approvals remain a key challenge.
Key Challenges and Opportunities
: Key Challenges:
- Clinical Trial Success: Portage's future success relies heavily on the successful completion of ongoing clinical trials and regulatory approval of its therapies.
- Competition: Intense competition from other companies developing RNA-based therapies for similar indications.
- Financing: Portage will need to raise additional capital to fund its ongoing clinical trials and commercialization efforts.
Opportunities:
- Portage's therapies target large unmet medical needs with significant market potential.
- Positive clinical data and successful commercialization could lead to substantial shareholder value creation.
- Partnerships with larger pharmaceutical companies could provide additional financial resources and development expertise.
Recent Acquisitions (last 3 years)
Portage Biotech has not made any acquisitions in the last three years.
AI-Based Fundamental Rating
Based on publicly available data and an AI-based analysis model, Portage Biotech Inc. receives a fundamental rating of 5.5 out of 10.
Reasons for this rating:
- Positives: Promising pipeline with two late-stage clinical candidates, strong leadership team, large addressable market.
- Negatives: No current revenue, significant operating losses, high clinical development risk.
Sources and Disclaimers
This overview is based on information obtained from the following sources:
- Portage Biotech Inc. website: https://www.portagebiotech.com/
- Securities and Exchange Commission (SEC) filings: https://www.sec.gov/edgar/searchedgar/companysearch.html
- Market research reports: https://www.grandviewresearch.com/industry-analysis/rna-therapeutics-market
- Disclaimer: This information is provided for educational purposes only and should not be considered financial advice. Investing involves inherent risks, and you should consult with a qualified financial professional before making any investment decisions.
I hope this comprehensive overview of Portage Biotech Inc. is helpful. Please let me know if you have any further questions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-25 | CEO & Chairman of Board Dr. Ian B. Walters M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.portagebiotech.com |
Full time employees 7 | Website https://www.portagebiotech.com |
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.